Valneva SE, a specialty vaccine company, was granted PRIority MEdicines (PRIME) designation by the European Medicines Agency (EMA)  for its single-shot Phase III chikungunya vaccine candidate VLA1553. This new designation from the EMA complements the Fast Track designation received by the U.S. FDA in December 2018. The PRIME designation is awarded to promising medicines that demonstrate the potential to address substantial unmet medical need based on initial clinical data. The EMA considers ...